These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20620013)

  • 1. Variation in management of early breast cancer in the Netherlands, 2003-2006.
    van Steenbergen LN; van de Poll-Franse LV; Wouters MW; Jansen-Landheer ML; Coebergh JW; Struikmans H; Tjan-Heijnen VC; van de Velde CJ
    Eur J Surg Oncol; 2010 Sep; 36 Suppl 1():S36-43. PubMed ID: 20620013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
    Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
    J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after negative extensive axillary dissection.
    Kuijt GP; van de Poll-Franse LV; Voogd AC; Nieuwenhuijzen GA; Roumen RM
    Eur J Surg Oncol; 2007 Sep; 33(7):832-7. PubMed ID: 17197151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between extent of axillary lymph node dissection and patient, tumor, surgeon, and hospital factors in patients with early breast cancer.
    Petrik DW; McCready DR; Sawka CA; Goel V
    J Surg Oncol; 2003 Feb; 82(2):84-90. PubMed ID: 12561062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axillary and systemic treatment of patients with breast cancer and micrometastatic disease or isolated tumor cells in the sentinel lymph node.
    Maaskant-Braat AJ; Voogd AC; van de Poll-Franse LV; Coebergh JW; Nieuwenhuijzen GA
    Breast; 2012 Aug; 21(4):524-8. PubMed ID: 22516371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005).
    Chen AY; Halpern MT; Schrag NM; Stewart A; Leitch M; Ward E
    J Natl Cancer Inst; 2008 Apr; 100(7):462-74. PubMed ID: 18364506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of sentinel node biopsy in breast cancer patients in the Netherlands.
    Ho VK; van der Heiden-van der Loo M; Rutgers EJ; van Diest PJ; Hobbelink MG; Tjan-Heijnen VC; Dirx MJ; Reedijk AM; van Dijck JA; van de Poll-Franse LV; Schaapveld M; Peeters PH
    Eur J Cancer; 2008 Mar; 44(5):683-91. PubMed ID: 18314328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time trends and inter-hospital variation in treatment and axillary staging of patients with ductal carcinoma in situ of the breast in the era of screening in Southern Netherlands.
    van Steenbergen LN; Voogd AC; Roukema JA; Louwman WJ; Duijm LE; Coebergh JW; van de Poll-Franse LV
    Breast; 2014 Feb; 23(1):63-8. PubMed ID: 24291376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
    Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
    J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axillary recurrence rate after tumour negative and micrometastatic positive sentinel node procedures in breast cancer patients, a population based multicenter study.
    Bulte CS; van der Heiden-van der Loo M; Hennipman A
    Eur J Surg Oncol; 2009 Jan; 35(1):25-31. PubMed ID: 18640809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature.
    Caliskan M; Gatti G; Sosnovskikh I; Rotmensz N; Botteri E; Musmeci S; Rosali dos Santos G; Viale G; Luini A
    Breast Cancer Res Treat; 2008 Dec; 112(3):513-21. PubMed ID: 18240020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of the axilla in breast cancer: evidences and unresolved issues].
    Fodor J; Polgár C; Péley G; Németh G
    Orv Hetil; 2001 Sep; 142(36):1941-50. PubMed ID: 11680099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Local relapse in young (< or = 40 years) women with breast cancer after mastectomy or breast conserving surgery: 15-year results].
    Fodor J; Mózsa E; Zaka Z; Polgár C; Major T
    Magy Onkol; 2005; 49(3):203, 205-8. PubMed ID: 16249814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in treatment and outcome of patients with rectal cancer by region, hospital type and volume in the Netherlands.
    Elferink MA; Krijnen P; Wouters MW; Lemmens VE; Jansen-Landheer ML; van de Velde CJ; Langendijk JA; Marijnen CA; Siesling S; Tollenaar RA
    Eur J Surg Oncol; 2010 Sep; 36 Suppl 1():S74-82. PubMed ID: 20598844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
    Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
    Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Explanatory factors for variation in the use of breast conserving surgery and radiotherapy in the Netherlands, 1990-2001.
    Siesling S; van de Poll-Franse LV; Jobsen JJ; Repelaer van Driel OJ; Voogd AC
    Breast; 2007 Dec; 16(6):606-14. PubMed ID: 17604628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution.
    Pass H; Vicini FA; Kestin LL; Goldstein NS; Decker D; Pettinga J; Ingold J; Benitez P; Neumann K; Rebner M; Dekhne N; Martinez A
    Cancer; 2004 Aug; 101(4):713-20. PubMed ID: 15305400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer.
    Bilimoria KY; Bentrem DJ; Hansen NM; Bethke KP; Rademaker AW; Ko CY; Winchester DP; Winchester DJ
    J Clin Oncol; 2009 Jun; 27(18):2946-53. PubMed ID: 19364968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of axillary recurrence after axillary lymph node dissection for invasive breast cancer.
    Voogd AC; de Boer R; van der Sangen MJ; Roumen RM; Rutten HJ; Coebergh JW
    Eur J Surg Oncol; 2001 Apr; 27(3):250-5. PubMed ID: 11373100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.